GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » Cyclically Adjusted Price-to-FCF

ESSA Pharma (ESSA Pharma) Cyclically Adjusted Price-to-FCF : (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


ESSA Pharma Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ESSA Pharma's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma Cyclically Adjusted Price-to-FCF Chart

ESSA Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ESSA Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ESSA Pharma's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, ESSA Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ESSA Pharma's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's Cyclically Adjusted Price-to-FCF falls into.



ESSA Pharma Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ESSA Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, ESSA Pharma's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.154/125.4675*125.4675
=-0.154

Current CPI (Dec. 2023) = 125.4675.

ESSA Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 0.010 98.604 0.013
201406 -0.925 99.473 -1.167
201409 -1.598 99.394 -2.017
201412 -2.708 98.367 -3.454
201503 -1.619 99.789 -2.036
201506 -5.599 100.500 -6.990
201509 -4.365 100.421 -5.454
201512 -2.302 99.947 -2.890
201603 -4.414 101.054 -5.480
201606 -2.332 102.002 -2.868
201609 -2.330 101.765 -2.873
201612 -4.114 101.449 -5.088
201703 -1.861 102.634 -2.275
201706 -3.275 103.029 -3.988
201709 -2.074 103.345 -2.518
201712 -1.335 103.345 -1.621
201803 -0.612 105.004 -0.731
201806 -0.486 105.557 -0.578
201809 -0.387 105.636 -0.460
201812 -0.294 105.399 -0.350
201903 -0.437 106.979 -0.513
201906 -0.391 107.690 -0.456
201909 -0.248 107.611 -0.289
201912 -0.162 107.769 -0.189
202003 -0.287 107.927 -0.334
202006 -0.167 108.401 -0.193
202009 -0.152 108.164 -0.176
202012 -0.118 108.559 -0.136
202103 -0.208 110.298 -0.237
202106 -0.159 111.720 -0.179
202109 -0.171 112.905 -0.190
202112 -0.132 113.774 -0.146
202203 -0.190 117.646 -0.203
202206 -0.143 120.806 -0.149
202209 -0.170 120.648 -0.177
202212 -0.099 120.964 -0.103
202303 -0.172 122.702 -0.176
202306 -0.075 124.203 -0.076
202309 -0.102 125.230 -0.102
202312 -0.154 125.468 -0.154

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ESSA Pharma  (NAS:EPIX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ESSA Pharma Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ESSA Pharma (ESSA Pharma) Business Description

Industry
Traded in Other Exchanges
N/A
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
Executives
Peter Virsik officer: Chief Operating Officer 131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson director, officer: Chief Executive Officer C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood officer: Chief Financial Officer 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104